Related Experiment Video
Updated: Sep 29, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Cancer and thromboembolic disease: pathogenic mechanisms
1Hamilton Health Sciences, Henderson Site, Ont, Canada L8V 1C3. alee@mcmaster.ca
Abstract:
Almost all types of cancer are associated with an activation of coagulation. However, elevation of haemostatic markers of coagulation does not predict venous thrombosis. Multiple and interdependent processes between the tumour and the patient induce a hypercoagulable state. Tumour procoagulant activity, host inflammatory responses and extrinsic factors are involved. Tumour cells express the procoagulants, tissue factor and cancer procoagulant. They also release inflammatory cytokines and vascular endothelial growth factor, substances that enhance procoagulant activity and angiogenesis. Tumour-induced coagulation is intrinsically involved with tumour growth, angiogenesis and metastasis.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

